Trastuzumab deruxtecan both significantly improved overall survival and yielded progression-free survival that was 4 times greater than trastuzumab emtansine in patients with HER2-positive metastatic breast cancer.
Trastuzumab and pertuzumab with a chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel increased response, and high-grade toxicity, in patients with HER2-positive gastric or gastroesophageal junction cancer.
During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.
The expansion of screening criteria is an important step in decreasing lung cancer screening disparities in high-risk populations. Efforts to expand community outreach, overcome logistical barriers, and facilitate screening adherence must still be made, experts say.
An updated safety and efficacy analysis of the ongoing CLL14 trial showed that venetoclax plus obinutuzumab continues to be an effective treatment for patients with chronic lymphocytic leukemia and coexisting conditions.